Exploratory Clinical Neuroscience Research on Substance Use Disorders

National Institutes of Health · HHS

CFDA Numbers

93.279

Award Ceiling

—

Award Floor

—

Expected Awards

Close Date

Jul 10, 2026

Section I

How to Apply

View on grants_gov ↗

Program Contact

NIDA_DNB_BCNB_r61@nih.gov
Please contact via e-mail.

Section II

Eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Eligible Applicant Types

00, 01, 02, 04, 05, 06, 07, 08, 11, 12, 13, 20, 22, 23, 25

Section III

Description

This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This NOFO is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)

Section IV

Key Dates

Posted: Jun 1, 2026
Closes: Jul 10, 2026